Abstract
Cellular repressor of E1A-stimulated genes (CREG), a novel cellular protein, was discovered in 1998. Accumulating evidence, mainly from our laboratory, has suggested that CREG plays critical roles in reducing neointimal hyperplasia, maintaining vascular homeostasis, and promoting endothelial restoration. The study of CREG has the potential to offer new insights into both prevention and treatment of proliferative vascular disease, and will help us understand the processes of vascular repair after injury. It will also contribute to the development of new therapeutic strategies and devices, such as anti-in-stent restenosis stents. The present review summarizes our research on the molecular identity of CREG, and reviews the biological activities of CREG in regulating cell differentiation, proliferation, migration, and apoptosis of vascular smooth muscle cells and endothelial cells.
Keywords: Atherosclerosis, CREG, EC, restenosis, VSMC, heart disease, myocardial infarction, ischemic heart failure, inflammatory disease, vascular endothelial injury, platelet adherence, atherosclerotic plaque, myocardial revascularization, coronary stents, hyperplasia
Current Molecular Medicine
Title:CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Volume: 12 Issue: 10
Author(s): Y. Li, C.-H. Yan, S.-H. Li and Y.-L. Han
Affiliation:
Keywords: Atherosclerosis, CREG, EC, restenosis, VSMC, heart disease, myocardial infarction, ischemic heart failure, inflammatory disease, vascular endothelial injury, platelet adherence, atherosclerotic plaque, myocardial revascularization, coronary stents, hyperplasia
Abstract: Cellular repressor of E1A-stimulated genes (CREG), a novel cellular protein, was discovered in 1998. Accumulating evidence, mainly from our laboratory, has suggested that CREG plays critical roles in reducing neointimal hyperplasia, maintaining vascular homeostasis, and promoting endothelial restoration. The study of CREG has the potential to offer new insights into both prevention and treatment of proliferative vascular disease, and will help us understand the processes of vascular repair after injury. It will also contribute to the development of new therapeutic strategies and devices, such as anti-in-stent restenosis stents. The present review summarizes our research on the molecular identity of CREG, and reviews the biological activities of CREG in regulating cell differentiation, proliferation, migration, and apoptosis of vascular smooth muscle cells and endothelial cells.
Export Options
About this article
Cite this article as:
Li Y., Yan C.-H., Li S.-H. and Han Y.-L., CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease, Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833526
DOI https://dx.doi.org/10.2174/156652412803833526 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
microRNAs as New Targets of Dietary Polyphenols
Current Pharmaceutical Biotechnology The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt with: A Review of Current and Potential Phosphate Binders (PB)
Mini-Reviews in Medicinal Chemistry Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design Statins and Solid Organ Transplantation
Current Pharmaceutical Design Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Editorial [ Hot Topic:Stroke Bugs: Current and Emerging Concepts Relevant to Infection in Cerebrovascular Disease (Guest Editors: Hedley CA Emsley and Angel Chamorro)]
Infectious Disorders - Drug Targets Molybdenum Metallopharmaceuticals Candidate Compounds - The “Renaissance” of Molybdenum Metallodrugs?
Current Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Current Vascular Pharmacology Virtual Screening Against Obesity
Current Medicinal Chemistry Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3
Current Cancer Drug Targets Dextran-based Drug Delivery Approaches for Lung Diseases: A Review
Current Drug Delivery Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist
Current Immunology Reviews (Discontinued) Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis